Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3321641 | 1.00 | ALDH1A1 (0.32) | ALDH1A1THRBRECQLL3MBTL1HSP90AA1 | |
| SCHEMBL1605045 | 0.80 | — | — | |
| SCHEMBL11360667 | 0.80 | CYP2C19 (0.37) | ALDH1A1THRBRECQLL3MBTL1HSP90AA1 | |
| SCHEMBL8199232 | 0.79 | SMN1; SMN2 (0.37) | ALDH1A1 | |
| SCHEMBL6218904 | 0.78 | — | — | |
| SCHEMBL5493506 | 0.76 | L3MBTL1 (0.32) | ALDH1A1L3MBTL1HSP90AA1MAPTGPR55 | |
| SCHEMBL3277859 | 0.75 | ALDH1A1 (0.39) | ALDH1A1CYP2C19 | |
| SCHEMBL10833159 | 0.75 | — | — | |
| SCHEMBL554253 | 0.75 | CYP3A4 (0.32) | — | |
| SCHEMBL10505362 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8263657-B2 | Blocking neurokinins; using a benzene compound containing hydroxy or acetoxy group; antiinflammatory agents | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2012-09-11 | — | — | US | disclosed |
| US-8097759-B2 | Inflammatory cytokine release inhibitor | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2012-01-17 | — | — | US | disclosed |
| US-20100274051-A1 | INFLAMMATORY CYTOKINE RELEASE INHIBITOR | INSTITUTE OF MEDICINAL MOLECULAR DESIGN. INC. (JP) | 2010-10-28 | — | — | US | disclosed |
| CN-1658872-B | Antiallergic agent | INST MED MOLECULAR DESIGN INC | 2010-09-22 | — | — | CN | disclosed |
| US-20100041683-A1 | NOVEL CHAIN-BREAKING ANTIOXIDANTS | PRATT DEREK A | 2010-02-18 | — | — | US | disclosed |
| US-7626042-B2 | O-substituted hydroxyaryl derivatives | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2009-12-01 | — | — | US | disclosed |
| US-20090192122-A2 | INFLAMMATORY CYTOKINE RELEASE INHIBITOR | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2009-07-30 | — | — | US | disclosed |
| CN-100506221-C | Cancer therapeutic agent | INST MED MOLECULAR DESIGN INC (JP) | 2009-07-01 | — | — | CN | disclosed |
| US-7547709-B2 | Chain-breaking antioxidants | VANDERBILT UNIVERSITY (US) | 2009-06-16 | — | — | US | disclosed |
| CN-100490793-C | Remedies for neurodegenerative diseases | INST MED MOLECULAR DESIGN INC (JP) | 2009-05-27 | — | — | CN | disclosed |
| US-5340815-A | Inhibitors of 5-lipoxygenase and/or cyclooxygenase | WARNER-LAMBERT COMPANY (US) | 1994-08-23 | — | — | US | disclosed |
| US-5302597-A | Enzyme inhibitors | WARNER-LAMBERT COMPANY (US) | 1994-04-12 | — | — | US | disclosed |
| US-5284949-A | 2-substituted amino-4,6-di-tertiary-butyl-5-hydroxy-1,3-pyrimidines as antiinflammatory agents | WARNER-LAMBERT COMPANY (US) | 1994-02-08 | — | — | US | disclosed |
| EP-0569491-A4 | 2-SUBSTITUTED-4,6-DI-TERTIARY-BUTYL-5-HYDROXY-1,3-PYRIMIDINES USEFUL AS ANTIINFLAMMATORY AGENTS | — | 1993-11-24 | — | — | EP | disclosed |
| EP-0569491-A1 | 2-SUBSTITUTED-4,6-DI-TERTIARY-BUTYL-5-HYDROXY-1,3-PYRIMIDINES USEFUL AS ANTIINFLAMMATORY AGENTS | WARNER-LAMBERT COMPANY (US) | 1993-11-18 | — | — | EP | disclosed |
| US-5248682-A | Inhibitors of lipoxygenase and cyclooxygenase | WARNER-LAMBERT COMPANY (US) | 1993-09-28 | — | — | US | disclosed |
| US-5220025-A | 2-substituted amino-4, 6-di-tertiary-butyl-5-hydroxy-1, 3-pyrimidines as antiinflammatory agents | WARNER-LAMBERT COMPANY (US) | 1993-06-15 | — | — | US | disclosed |
| US-5196431-A | 2-substituted amino-4, 6-di-tertiary-buthyl-5-hydroxy-1, 3-pyrimidines as antiinflammatory agents | WARNER-LAMBERT COMPANY (US) | 1993-03-23 | — | — | US | disclosed |
| US-5177079-A | Antiallergen, antiulcer | WARNER-LAMBERT COMPANY (US) | 1993-01-05 | — | — | US | disclosed |
| WO-1992013536-A1 | 2-SUBSTITUTED-4,6-DI-TERTIARY-BUTYL-5-HYDROXY-1,3-PYRIMIDINES USEFUL AS ANTIINFLAMMATORY AGENTS | WARNER-LAMBERT COMPANY (US) | 1992-08-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100274051-A1 | INFLAMMATORY CYTOKINE RELEASE INHIBITOR | IL1B, NFKBIA, IL1A | ALDH1A1 479/4885THRB 750/4885RECQL 3908/4885 |
| US-20090192122-A2 | INFLAMMATORY CYTOKINE RELEASE INHIBITOR | IL1B, NFKBIA, IL1A | ALDH1A1 563/4885THRB 966/4885RECQL 3848/4885 |
| US-20100041683-A1 | NOVEL CHAIN-BREAKING ANTIOXIDANTS | TTPA, GPX4, PNPO | ALDH1A1 704/4885THRB 3833/4885RECQL 62/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.